Advances in the discovery and development of trematocidal drugs

Bibliography

• KEISER J, UTZINGER J: Food-borne trematodiasis: current chemotherapy and advances with artemisinins and synthetic trioxolanes. Trends Parasitol. (2007) (In Press).
   Google Scholar
• UTZINGER J, XIAO SH, TANNER M, KEISER J: Artemisinins for schistosomiasis and beyond. Curr. Opin. Investig. Drugs (2007) 8:105-116.
   PubMed Web of Science ®Google Scholar
• BRADY MA, HOOPER PJ, OTTESEN EA: Projected benefits from integrating NTD programs in sub-Saharan Africa. Trends Parasitol. (2006) 22:285-291.
   PubMed Web of Science ®Google Scholar
• ENGELS D, SAVIOLI L: Reconsidering the underestimated burden caused by neglected tropical diseases. Trends Parasitol. (2006) 22:363-366.
   PubMed Web of Science ®Google Scholar
• LAMMIE PJ, FENWICK A, UTZINGER J: A blueprint for success: integration of neglected tropical disease control programmes. Trends Parasitol. (2006) 22:313-321.
   PubMed Web of Science ®Google Scholar
• BROOKER S, UTZINGER J: Integrated disease mapping in a polyparasitic world. Geospatial Health (2007) 1:141-146.
   PubMed Web of Science ®Google Scholar
• REMME JHF, BLAS E, CHITSULO L et al.: Strategic emphases for tropical diseases research: a TDR perspective. Trends Parasitol. (2002) 18:421-426.
   PubMed Web of Science ®Google Scholar
• RIDLEY RG: Product R&D for neglected diseases. Twenty-seven years of WHO/TDR experiences with public-private partnerships. EMBO Rep. (2003) 4:S43-S46.
   PubMed Web of Science ®Google Scholar
• NWAKA S, HUDSON A: Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. (2006) 5:941-955.
   PubMed Web of Science ®Google Scholar
• HOTEZ PJ, MOLYNEUX DH, FENWICK A, OTTESEN E, EHRLICH SACHS S, SACHS JD: Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med. (2006) 3:e102.
   PubMed Web of Science ®Google Scholar
• GRYSEELS B, POLMAN K, CLERINX J, KESTENS L: Human schistosomiasis. Lancet (2006) 368:1106-1118.
   PubMed Web of Science ®Google Scholar
• WHO: Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. WHO Tech. Rep. Ser. No. 912. World Health Organization, Geneva (2002).
   Google Scholar
• UTZINGER J, KEISER J: Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin. Pharmacother. (2004) 5:263-285.
   PubMed Web of Science ®Google Scholar
• STEINMANN P, KEISER J, BOS R, TANNER M, UTZINGER J: Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect. Dis. (2006) 6:411-425.
   PubMed Web of Science ®Google Scholar
• DAVIS A: Schistosomiasis. In: Manson's Tropical Diseases, 21st Edition. Cook GC, Zumla AI (Eds), Saunders, London (2003):1431-1469.
   Google Scholar
• VAN DER WERF MJ, DE VLAS SJ, BROOKER S et al.: Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. (2003) 86:125-139.
   PubMed Web of Science ®Google Scholar
• KEISER J, UTZINGER J: Emerging foodborne trematodiasis. Emerg. Infect. Dis. (2005) 11:1507-1514.
   PubMed Web of Science ®Google Scholar
• HASWELL-ELKINS M, LEVRI E: Food-borne trematodes. In: Manson's Tropical Diseases, 21st Edition. Cook GC, Zumla AI (Eds), Saunders, London (2003):1471-1486.
   Google Scholar
• UTZINGER J, DE SAVIGNY D: Control of neglected tropical diseases: integrated chemotherapy and beyond. PLoS Med. (2006) 3:e112.
   PubMedGoogle Scholar
• MCMANUS DP, DALTON JP: Vaccines against the zoonotic trematodes Schistosoma japonicum, Fasciola hepatica and Fasciola gigantica. Parasitology (2006) 133:S43-S61.
   PubMed Web of Science ®Google Scholar
• LÓPEZ-ABÁN J, CASANUEVA P, NOGAL J et al.: Progress in the development of Fasciola hepatica vaccine using recombinant fatty acid binding protein with the adjuvant adaptation system ADAD. Vet. Parasitol. (2007) 145:287-296.
   PubMed Web of Science ®Google Scholar
• LOUKAS A, TRAN M, PEARSON MS: Schistosome membrane proteins as vaccines. Int. J. Parasitol. (2007) 37:257-263.
   PubMed Web of Science ®Google Scholar
• WHO: Control of foodborne trematode infections. Report of a WHO study group. WHO Tech. Rep. Ser. No. 849. World Health Organization, Geneva (1995).
   Google Scholar
• KEISER J, UTZINGER J: Chemotherapy for major food-borne trematode infections: a review. Expert Opin. Pharmacother. (2004) 5:1711-1726.
   PubMed Web of Science ®Google Scholar
• WHITE N: Antimalarial drug resistance and combination chemotherapy. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (1999) 354:739-749.
   PubMed Web of Science ®Google Scholar
• CIOLI D: Chemotherapy of schistosomiasis: an update. Parasitol. Today (1998) 14:418-422.
   PubMedGoogle Scholar
• FENWICK A, KEISER J, UTZINGER J: Epidemiology, burden and control of schistosomiasis with particular consideration to past and current treatment trends. Drug Future (2006) 31:413-425.
   Web of Science ®Google Scholar
• KEISER J, ENGELS D, BÜSCHER G, UTZINGER J: Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin. Investig. Drugs (2005) 14:1513-1526.
   PubMed Web of Science ®Google Scholar
• CIOLI D, PICA-MATTOCCIA L: Praziquantel. Parasitol. Res. (2003) 90:S3-S9.
   PubMed Web of Science ®Google Scholar
• GRYSEELS B, MBAYE A, DE VLAS SJ et al.: Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop. Med. Int. Health (2001) 6:864-873.
   PubMed Web of Science ®Google Scholar
• DANSO-APPIAH A, DE VLAS SJ: Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol. (2002) 18:125-129.
   PubMed Web of Science ®Google Scholar
• ISMAIL M, BOTROS S, METWALLY A et al.: Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am. J. Trop. Med. Hyg. (1999) 60:932-935.
   PubMed Web of Science ®Google Scholar
• WILLIAM S, BOTROS S, ISMAIL M, FARGHALLY A, DAY TA, BENNETT JL: Praziquantel-induced tegumental damage in vitro is diminished in schistosomes derived from praziquantel-resistant infections. Parasitology (2001) 122:63-66.
   PubMed Web of Science ®Google Scholar
• CIOLI D, BOTROS SS, WHEATCROFT-FRANCKLOW K et al.: Determination of ED50 values for praziquantel in praziquantel-resistant and susceptible Schistosoma mansoni isolates. Int. J. Parasitol. (2004) 34:979-987.
   PubMed Web of Science ®Google Scholar
• TINGA N, DE N, VIEN HV et al.: Little effect of praziquantel or artemisinin on clonorchiasis in Northern Vietnam. A pilot study. Trop. Med. Int. Health (1999) 4:814-818.
   PubMed Web of Science ®Google Scholar
• LAWN SD, LUCAS SB, CHIODINI PL: Schistosoma mansoni infection: failure of standard treatment with praziquantel in a returned traveller. Trans. R. Soc. Trop. Med. Hyg. (2003) 97:100-101.
   PubMed Web of Science ®Google Scholar
• ALONSO D, MUÑOZ J, GASCÓN J, VALLS ME, CORACHAN M: Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am. J. Trop. Med. Hyg. (2006) 74:342-344.
   PubMed Web of Science ®Google Scholar
• SABAH AA, FLETCHER C, WEBBE G, DOENHOFF MJ: Schistosoma mansoni: chemotherapy of infections of different ages. Exp. Parasitol. (1986) 61:294-303.
   PubMed Web of Science ®Google Scholar
• UTZINGER J, KEISER J, XIAO SH, TANNER M, SINGER BH: Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob. Agents Chemother. (2003) 47:1487-1495.
   PubMed Web of Science ®Google Scholar
• RASO G, N'GORAN EK, TOTY A et al.: Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Côte d'Ivoire. Trans. R. Soc. Trop. Med. Hyg. (2004) 98:18-27.
   PubMed Web of Science ®Google Scholar
• STEINMEYER A: The hit-to-lead process at Schering AG: strategic aspects. Chem. Med. Chem. (2006) 1:31-36.
   Google Scholar
• ZHENG CJ, HAN LY, YAP CW, XIE B, CHEN YZ: Progress and problems in the exploration of therapeutic targets. Drug Discov. Today (2006) 11:412-420.
   PubMed Web of Science ®Google Scholar
• NICHOLSON JK, CONNELLY J, LINDON JC, HOLMES E: Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug. Discov. (2002) 1:153-161.
   PubMed Web of Science ®Google Scholar
• STOUGHTON RB, FRIEND SH: How molecular profiling could revolutionize drug discovery. Nat. Rev. Drug. Discov. (2005) 4:345-350.
   PubMed Web of Science ®Google Scholar
• JONES AK, BENTLEY GN, OLIVEROS PARRA WG, AGNEW A: Molecular characterization of an acetylcholinesterase implicated in the regulation of glucose scavenging by the parasite Schistosoma. FASEB J. (2002) 16:441-443.
   PubMed Web of Science ®Google Scholar
• BENTLEY GN, JONES AK, AGNEW A: Mapping and sequencing of acetylcholinesterase genes from the platyhelminth blood fluke Schistosoma. Gene (2003) 314:103-112.
   PubMed Web of Science ®Google Scholar
• RAO KV, CHEN L, GNANASEKAR M, RAMASWAMY K: Cloning and characterization of a calcium-binding, histamine-releasing protein from Schistosoma mansoni. J. Biol. Chem. (2002) 277:31207-31213.
   PubMed Web of Science ®Google Scholar
• KOHN AB, ANDERSON PA, ROBERTS-MISTERLY JM, GREENBERG RM: Schistosome calcium channel β-subunits. Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. J. Biol. Chem. (2001) 276:36873-36876.
   PubMed Web of Science ®Google Scholar
• AGBOH KC, WEBB TE, EVANS RJ, ENNION SJ: Functional characterization of a P2X receptor from Schistosoma mansoni. J. Biol. Chem. (2004) 279:41650-41657.
   PubMed Web of Science ®Google Scholar
• PEREIRA HM, CLEASBY A, PENA SS, FRANCO GG, GARRATT RC: Cloning, expression and preliminary crystallographic studies of the potential drug target purine nucleoside phosphorylase from Schistosoma mansoni. Acta Crystallogr. D. Biol. Crystallogr. (2003) 59:1096-1099.
   PubMed Web of Science ®Google Scholar
• PEREIRA HD, FRANCO GR, CLEASBY A, GARRATT RC: Structures for the potential drug target purine nucleoside phosphorylase from Schistosoma mansoni causal agent of schistosomiasis. J. Mol. Biol. (2005) 353:584-599.
   PubMed Web of Science ®Google Scholar
• FOULK BW, PAPPAS G, HIRAI Y, HIRAI H, WILLIAMS DL: Adenylosuccinate lyase of Schistosoma mansoni: gene structure, mRNA expression, and analysis of the predicted peptide structure of a potential chemotherapeutic target. Int. J. Parasitol. (2002) 32:1487-1495.
   PubMed Web of Science ®Google Scholar
• OLIVEIRA MF, D'AVILA JC, TEMPONE AJ et al.: Inhibition of heme aggregation by chloroquine reduces Schistosoma mansoni infection. J. Infect. Dis. (2004) 190:843-852.
   PubMed Web of Science ®Google Scholar
• CAFFREY CR, PLACHA L, BARINKA C et al.: Homology modeling and SAR analysis of Schistosoma japonicum cathepsin D (SjCD) with statin inhibitors identify a unique active site steric barrier with potential for the design of specific inhibitors. Biol. Chem. (2005) 386:339-349.
   PubMed Web of Science ®Google Scholar
• BAHIA D, ANDRADE LF, LUDOLF F, MORTARA RA, OLIVEIRA G: Protein tyrosine kinases in Schistosoma mansoni. Mem. Inst. Oswaldo Cruz. (2006) 101:137-143.
   PubMedGoogle Scholar
• SAYED AA, WILLIAMS DL: Biochemical characterization of 2-Cys peroxiredoxins from Schistosoma mansoni. J. Biol. Chem. (2004) 279:26159-26166.
   PubMed Web of Science ®Google Scholar
• SAYED AA, COOK SK, WILLIAMS DL: Redox balance mechanisms in Schistosoma mansoni rely on peroxiredoxins and albumin and implicate peroxiredoxins as novel drug targets. J. Biol. Chem. (2006) 281:17001-17010.
   PubMed Web of Science ®Google Scholar
• KEISER J, XIAO SH, CHOLLET J, TANNER M, UTZINGER J: Evaluation of the in vivo activity of tribendimidine against Schistosoma mansoni, Fasciola hepatica, Clonorchis sinensis, and Opisthorchis viverrini. Antimicrob. Agents Chemother. (2007) 51:1096-1098.
   PubMed Web of Science ®Google Scholar
• KEISER J, EL ELA NA, EL KOMY E et al.: Triclabendazole and its two main metabolites lack activity against Schistosoma mansoni in the mouse model. Am. J. Trop. Med. Hyg. (2006) 75:287-291.
   PubMed Web of Science ®Google Scholar
• MASSOUD AMA, EL EBIARY FH, ABOU-GAMRA MMM, MOHAMED GF, SHAKER SM: Evaluation of schistosomicidal activity of myrrh extract: parasitological and histological study. J. Egypt Soc. Parasitol. (2004) 34:1051-1076.
   PubMedGoogle Scholar
• BOTROS S, WILLIAM S, EBEID F et al.: Lack of evidence for an antischistosomal activity of myrrh in experimental animals. Am. J. Trop. Med. Hyg. (2004) 71:206-210.
   PubMed Web of Science ®Google Scholar
• SOLIMAN MF, IBRAHIM MM: Antischistosomal action of atorvastatin alone and concurrently with medroxyprogesterone acetate on Schistosoma haematobium harboured in hamster: surface ultrastructure and parasitological study. Acta Trop. (2005) 93:1-9.
   PubMed Web of Science ®Google Scholar
• NESSIM NG, MAHMOUD S: Prophylactic effect of the anti-inflammatory drug diclofenac in experimental schistosomiasis mansoni. Int. J. Infect. Dis. (2006) 11:161-165.
   PubMed Web of Science ®Google Scholar
• BOTROS S, WILLIAM S, HAMMAM O, ZIDEK Z, HOLY A: Activity of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine against schistosomiasis mansoni in mice. Antimicrob. Agents Chemother. (2003) 47:3853-3858.
   PubMed Web of Science ®Google Scholar
• DE MELO AL, SILVA-BARCELLOS NM, DEMICHELI C, FREZARD F: Enhanced schistosomicidal efficacy of tartar emetic encapsulated in pegylated liposomes. Int. J. Pharm. (2003) 255:227-230.
   PubMedGoogle Scholar
• ABDULLA MH, LIM KC, SAJID M, MCKERROW JH, CAFFREY CR: Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med. (2007) 4:e14.
   PubMed Web of Science ®Google Scholar
• BONN D: Schistosomiasis: a new target for calcium channel blockers. Lancet Infect. Dis. (2004) 4:190.
   PubMedGoogle Scholar
• FILHO RP, DE SOUZA MENEZES CM, PINTO PL, PAULA GA, BRANDT CA, DA SILVEIRA MA: Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs. Bioorg. Med. Chem. (2007) 15:1229-1236.
   PubMed Web of Science ®Google Scholar
• VENNERSTROM JL, ARBE-BARNES S, BRUN R et al.: Identification of an antimalarial synthetic trioxolane drug development candidate. Nature (2004) 430:900-904.
   PubMed Web of Science ®Google Scholar
• XIAO SH, KEISER J, CHOLLET J et al.: In vitro and in vivo activities of synthetic trioxolanes on major human schistosome species. Antimicrob. Agents Chemother. (2007) 51:1440-1445.
   PubMed Web of Science ®Google Scholar
• UTZINGER J, XIAO SH, N'GORAN EK, BERGQUIST R, TANNER M: The potential of artemether for the control of schistosomiasis. Int. J. Parasitol. (2001) 31:1549-1562.
   PubMed Web of Science ®Google Scholar
• XIAO SH, TANNER M, N'GORAN EK et al.: Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop. (2002) 82:175-181.
   PubMed Web of Science ®Google Scholar
• XIAO SH, CATTO BA: In vitro and in vivo studies of the effect of artemether on Schistosoma mansoni. Antimicrob. Agents Chemother. (1989) 33:1557-1562.
   PubMed Web of Science ®Google Scholar
• XIAO SH, CHOLLET J, WEISS NA, BERGQUIST RN, TANNER M: Preventive effect of artemether in experimental animals infected with Schistosoma mansoni. Parasitol. Int. (2000) 49:19-24.
   PubMed Web of Science ®Google Scholar
• XIAO SH, UTZINGER J, CHOLLET J, ENDRISS Y, N'GORAN EK, TANNER M: Effect of artemether against Schistosoma haematobium in experimentally infected hamsters. Int. J. Parasitol. (2000) 30:1001-1006.
   PubMed Web of Science ®Google Scholar
• JIRAUNGKOORSKUL W, SAHAPHONG S, SOBHON P, RIENGROJPITAK S, KANGWANRANGSAN N: Effects of praziquantel and artesunate on the tegument of adult Schistosoma mekongi harboured in mice. Parasitol. Int. (2005) 54:177-183.
   PubMed Web of Science ®Google Scholar
• JIRAUNGKOORSKUL W, SAHAPHONG S, SOBHON P, RIENGROJPITAK S, KANGWANRANGSAN N: Schistosoma mekongi: the in vitro effect of praziquantel and artesunate on the adult fluke. Exp. Parasitol. (2006) 113:16-23.
   PubMed Web of Science ®Google Scholar
• XIAO SH, CHOLLET J, UTZINGER J, MATILE H, MEI JY, TANNER M: Artemether administered together with haemin damages schistosomes in vitro. Trans. R. Soc. Trop. Med. Hyg. (2001) 95:67-71.
   PubMed Web of Science ®Google Scholar
• MESHNICK SR: Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. (2002) 32:1655-1660.
   PubMed Web of Science ®Google Scholar
• IBARRA F, VERA Y, QUIROZ H et al.: Determination of the effective dose of an experimental fasciolicide in naturally and experimentally infected cattle. Vet. Parasitol. (2004) 120:65-74.
   PubMed Web of Science ®Google Scholar
• VERA MONTENEGRO Y, IBARRA VELARDE F, LIEBANO HERNANDEZ E et al.: Efficacy of an experimental fasciolicide against immature and mature Fasciola hepatica in artificially infected calves. Parasitol. Res. (2004) 92:211-214.
   PubMed Web of Science ®Google Scholar
• VERA Y, IBARRA F, CANTO GJ, SORIA O, CASTILLO R, HERNANDEZ A: Determination of the maximum tolerated dose and the safety index of an experimental fasciolicide in cattle. J. Vet. Med. B. Infect. Dis. Vet. Public Health (2006) 53:145-149.
   PubMedGoogle Scholar
• KEISER J, BRUN R, FRIED B, UTZINGER J: Trematocidal activity of praziquantel and artemisinin derivatives: in vitro and in vivo investigations with adult Echinostoma caproni. Antimicrob. Agents Chemother. (2006) 50:803-805.
   PubMed Web of Science ®Google Scholar
• KEISER J, XIAO SH, TANNER M, UTZINGER J: Artesunate and artemether are effective fasciolicides in the rat model and in vitro. J. Antimicrob. Chemother. (2006) 57:1139-1145.
   PubMed Web of Science ®Google Scholar
• KEISER J, UTZINGER J, TANNER M, DONG Y, VENNERSTROM JL: The synthetic peroxide OZ78 is effective against Echinostoma caproni and Fasciola hepatica. J. Antimicrob. Chemother. (2006) 58:1193-1197.
   PubMed Web of Science ®Google Scholar
• KEISER J, XIAO SH, XUE J et al.: Effect of artesunate and artemether against Clonorchis sinensis and Opisthorchis viverrini in rodent models. Int. J. Antimicrob. Agents (2006) 28:370-373.
   PubMed Web of Science ®Google Scholar
• KEISER J, XIAO SH, DONG Y, UTZINGER J, VENNERSTROM JL: Clonorchicidal properties of the synthetic trioxolane OZ78. J. Parasitol. (2007) 93:(In Press).
   PubMedGoogle Scholar
• WHO: Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. World Health Organization, Geneva (2006).
   Google Scholar
• UTZINGER J, N'GORAN EK, N'DRI A, LENGELER C, XIAO SH, TANNER M: Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet (2000) 355:1320-1325.
   PubMed Web of Science ®Google Scholar
• N'GORAN EK, UTZINGER J, GNAKA HN et al.: Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections. Am. J. Trop. Med. Hyg. (2003) 68:24-32.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ D, VERCRUYSSE J, VERLÉ P, KONGS A, DIOP M: What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections? Trop. Med. Int. Health (2000) 5:744-746.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ D, VERCRUYSSE J, VERLÉ P, NIASSE F, KONGS A, DIOP M: Efficacy of artesunate against Schistosoma mansoni infections in Richard Toll, Senegal. Trans. R. Soc. Trop. Med. Hyg. (2000) 94:90-91.
   PubMed Web of Science ®Google Scholar
• BORRMANN S, SZLEZÁK N, FAUCHER J-F et al.: Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study. J. Infect. Dis. (2001) 184:1363-1366.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ D, VERCRUYSSE J, KONGS A, VERLÉ P, DOMPNIER JP, FAYE PC: Efficacy of artesunate and praziquantel in Schistosoma haematobium infected schoolchildren. Acta Trop. (2002) 82:61-66.
   PubMed Web of Science ®Google Scholar
• INYANG-ETOH PC, EJEZIE GC, USEH MF, INYANG ETOH EC: Efficacy of artesunate in the treatment of urinary schistosomiasis in an endemic community in Nigeria. Ann. Trop. Med. Parasitol. (2004) 98:491-499.
   PubMed Web of Science ®Google Scholar
• BOULANGER D, DIENG Y, CISSE B et al.: Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. Trans. R. Soc. Trop. Med. Hyg. (2007) 101:113-116.
   PubMed Web of Science ®Google Scholar
• ADAM I, ELHARDELLO OA, ELHADI MO, ABDALLA E, ELMARDI KA, HANSEN FJ: Antischistosomal efficacy of artesunate plus sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine administered as treatment for uncomplicated Plasmodium falciparum malaria. Ann. Trop. Med. Parasitol. (In Press).
   Google Scholar
• WHO: The use of artemisinin and its derivatives as anti-malarial drugs. Report of a joint CTD/DMP/TDR informal consultation. World Health Organization, Geneva (1998).
   Google Scholar
• MUTABINGWA TK: Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy! Acta Trop. (2005) 95:305-315.
   PubMed Web of Science ®Google Scholar
• SHEIR Z, NASR AA, MASSOUD A et al.: A safe, effective, herbal antischistosomal therapy derived from myrrh. Am. J. Trop. Med. Hyg. (2001) 65:700-704.
   PubMed Web of Science ®Google Scholar
• SOLIMAN OE, EL-ARMAN M, ABDUL-SAMIE ER, EL-NEMR HI, MASSOUD A: Evaluation of myrrh (Mirazid) therapy in fascioliasis and intestinal schistosomiasis in children: immunological and parasitological study. J. Egypt Soc. Parasitol. (2004) 34:941-966.
   PubMedGoogle Scholar
• ABO-MADYAN AA, MORSY TA, MOTAWEA SM: Efficacy of myrrh in the treatment of schistosomiasis (haematobium and mansoni) in Ezbet El-Bakly, Tamyia Center, El-Fayoum Governorate, Egypt. J. Egypt Soc. Parasitol. (2004) 34:423-446.
   PubMedGoogle Scholar
• BOTROS S, SAYED H, EL-DUSOKI H et al.: Efficacy of mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni-infected school children and households. Am. J. Trop. Med. Hyg. (2005) 72:119-123.
   PubMed Web of Science ®Google Scholar
• BARAKAT R, ELMORSHEDY H, FENWICK A: Efficacy of myrrh in the treatment of human schistosomiasis mansoni. Am. J. Trop. Med. Hyg. (2005) 73:365-367.
   PubMed Web of Science ®Google Scholar
• FENWICK A, WEBSTER JP: Schistosomiasis: challenges for control, treatment and drug resistance. Curr. Opin. Infect. Dis. (2006) 19:577-582.
   PubMed Web of Science ®Google Scholar
• XIAO SH, YOU JQ, MEI JY, GUO HF, JIAO PY, TANNER M: Effect of praziquantel together with artemether on Schistosoma japonicum parasites of different ages in rabbits. Parasitol. Int. (2000) 49:25-30.
   PubMed Web of Science ®Google Scholar
• UTZINGER J, CHOLLET J, YOU JQ, MEI JY, TANNER M, XIAO SH: Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals. Acta Trop. (2001) 80:9-18.
   PubMed Web of Science ®Google Scholar
• CIOLI D, PICA-MATTOCCIA L, ARCHER S: Antischistosomal drugs: past, present … and future? Pharmacol. Ther. (1995) 68:35-85.
   PubMed Web of Science ®Google Scholar
• CASTRO N, MEDINA R, SOTELO J, JUNG H: Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob. Agents Chemother. (2000) 44:2903-2904.
   PubMed Web of Science ®Google Scholar
• CASTRO N, JUNG H, MEDINA R, GONZALEZ-ESQUIVEL D, LOPEZ M, SOTELO J: Interaction between grapefruit juice and praziquantel in humans. Antimicrob. Agents Chemother. (2002) 46:1614-1616.
   PubMed Web of Science ®Google Scholar
• MOURAO SC, COSTA PI, SALGADO HR, GREMIAO MP: Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int. J. Pharm. (2005) 295:157-162.
   PubMed Web of Science ®Google Scholar
• RENGANATHAN E, CIOLI D: An international initiative on praziquantel use. Parasitol. Today (1998) 14:390-391.
   PubMedGoogle Scholar
• KUSEL J, HAGAN P: Praziquantel - its use, cost and possible development of resistance. Parasitol. Today (1999) 15:352-354.
   PubMedGoogle Scholar
• DOENHOFF M, KIMANI G, CIOLI D: Praziquantel and the control of schistosomiasis. Parasitol. Today (2000) 16:364-366.
   PubMedGoogle Scholar
• APPLETON CC, MBAYE A: Praziquantel – quality, dosages and markers of resistance. Trends Parasitol. (2001) 17:356-357.
   PubMedGoogle Scholar
• SULAIMAN SM, TRAORE M, ENGELS D, HAGAN P, CIOLI D: Counterfeit praziquantel. Lancet (2001) 358:666-667.
   PubMed Web of Science ®Google Scholar
• OLSEN A: Efficacy and safety of drug combinations in the treatment of schistosomiasis, soil-transmitted helminthiasis, lymphatic filariasis and onchocerciasis. Trans. R. Soc. Trop. Med. Hyg. (2007) 101:747-758.
   PubMed Web of Science ®Google Scholar
• PLOS MEDICINE EDITORS: A new era of hope for the world's most neglected diseases. PLoS Med. (2005) 2:e323.
   PubMedGoogle Scholar
• PINK R, HUDSON A, MOURIÈS MA, BENDIG M: Opportunities and challenges in antiparasitic drug discovery. Nat. Rev. Drug Discov. (2005) 4:727-740.
   PubMed Web of Science ®Google Scholar
• MORAN M: A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med. (2005) 2:e302.
   PubMed Web of Science ®Google Scholar
• NATH J, KRISHNA G: Safety screening of drugs in cancer therapy. Acta Haematol. (1998) 99:138-147.
   PubMed Web of Science ®Google Scholar